Biocure Technology Inc. (BICTF)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -1.05 Million CAD | -56.21% |
| 2022 | -673.72 Thousand USD | 52.73% |
| 2021 | -1.42 Million CAD | 41.26% |
| 2020 | -2.42 Million CAD | 31.54% |
| 2019 | -3.54 Million CAD | 45.06% |
| 2018 | -6.45 Million CAD | -35.76% |
| 2017 | -4.75 Million CAD | -138.7% |
| 2016 | -1.99 Million CAD | -209412.39% |
| 2015 | -950.18 CAD | -101.15% |
| 2014 | 82.32 Thousand CAD | -2.66% |
| 2013 | 84.57 Thousand CAD | -32.74% |
| 2012 | 125.74 Thousand CAD | 217.49% |
| 2011 | -107.02 Thousand CAD | 28.49% |
| 2010 | -149.67 Thousand CAD | -67.58% |
| 2009 | -89.31 Thousand CAD | -97.77% |
| 2008 | -45.16 Thousand CAD | -850.66% |
| 2007 | 6016.00 CAD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -46.23 Thousand USD | -28.04% |
| 2024 Q1 | -49.42 Thousand USD | 46.98% |
| 2023 Q4 | -93.21 Thousand USD | -130.86% |
| 2023 Q1 | -59.81 Thousand USD | 79.3% |
| 2023 Q2 | -75.8 Thousand USD | -26.75% |
| 2023 FY | -1.05 Million CAD | -56.21% |
| 2023 Q3 | -40.37 Thousand USD | 46.74% |
| 2022 Q2 | -196.62 Thousand CAD | 18.49% |
| 2022 Q4 | -288.94 Thousand USD | -75.47% |
| 2022 Q3 | -164.67 Thousand CAD | 16.25% |
| 2022 FY | -673.72 Thousand USD | 52.73% |
| 2022 Q1 | -241.21 Thousand CAD | -155.44% |
| 2021 Q1 | -1.08 Million CAD | 28.85% |
| 2021 Q3 | -1.17 Million CAD | 8.03% |
| 2021 Q2 | -1.28 Million CAD | -18.1% |
| 2021 Q4 | 435.09 Thousand CAD | 136.92% |
| 2021 FY | -1.42 Million CAD | 41.26% |
| 2020 Q4 | -1.52 Million CAD | -287.93% |
| 2020 Q2 | -436.21 Thousand CAD | 28.24% |
| 2020 Q3 | -393.11 Thousand CAD | 9.88% |
| 2020 Q1 | -607.83 Thousand CAD | 60.23% |
| 2020 FY | -2.42 Million CAD | 31.54% |
| 2019 Q3 | -695.15 Thousand CAD | 62.07% |
| 2019 FY | -3.54 Million CAD | 45.06% |
| 2019 Q2 | -1.83 Million CAD | -240.42% |
| 2019 Q1 | -538.36 Thousand CAD | 50.41% |
| 2019 Q4 | -1.52 Million CAD | -119.87% |
| 2018 FY | -6.45 Million CAD | -35.76% |
| 2018 Q4 | -1.08 Million CAD | -114.4% |
| 2018 Q3 | -506.39 Thousand CAD | 86.84% |
| 2018 Q2 | -3.84 Million CAD | -280.98% |
| 2018 Q1 | -1.01 Million CAD | 68.35% |
| 2017 FY | -4.75 Million CAD | -138.7% |
| 2017 Q1 | -296.77 CAD | -32.14% |
| 2017 Q3 | 26.59 Thousand CAD | 23.12% |
| 2017 Q2 | 21.6 Thousand CAD | 7378.77% |
| 2017 Q4 | -3.19 Million CAD | -12099.83% |
| 2016 Q1 | 10.25 Thousand CAD | -69.7% |
| 2016 FY | -1.99 Million CAD | -209412.39% |
| 2016 Q3 | 38.78 Thousand CAD | 170.32% |
| 2016 Q4 | -224.59 CAD | -100.58% |
| 2016 Q2 | 14.34 Thousand CAD | 39.95% |
| 2015 Q3 | 15.55 Thousand CAD | -1.76% |
| 2015 Q4 | 33.83 Thousand CAD | 117.53% |
| 2015 Q2 | 15.83 Thousand CAD | -22.35% |
| 2015 FY | -950.18 CAD | -101.15% |
| 2015 Q1 | 20.38 Thousand CAD | 24.33% |
| 2014 Q1 | 21.94 Thousand CAD | 21.3% |
| 2014 Q2 | 21.45 Thousand CAD | -2.25% |
| 2014 Q3 | -24.08 Thousand CAD | -212.28% |
| 2014 Q4 | 16.39 Thousand CAD | 168.08% |
| 2014 FY | 82.32 Thousand CAD | -2.66% |
| 2013 FY | 84.57 Thousand CAD | -32.74% |
| 2013 Q4 | 18.09 Thousand CAD | -28.49% |
| 2013 Q2 | 19.24 Thousand CAD | -58.02% |
| 2013 Q3 | 25.29 Thousand CAD | 31.46% |
| 2013 Q1 | 45.84 Thousand CAD | 92.95% |
| 2012 Q4 | 23.75 Thousand CAD | 41.41% |
| 2012 Q3 | 16.8 Thousand CAD | -57.29% |
| 2012 Q1 | -22.37 Thousand CAD | 20.37% |
| 2012 Q2 | 39.34 Thousand CAD | 275.82% |
| 2012 FY | 125.74 Thousand CAD | 217.49% |
| 2011 Q3 | 13.31 Thousand CAD | 130.8% |
| 2011 Q1 | 75.19 Thousand CAD | 145.39% |
| 2011 Q2 | -43.23 Thousand CAD | -157.49% |
| 2011 FY | -107.02 Thousand CAD | 28.49% |
| 2011 Q4 | -28.1 Thousand CAD | -311.03% |
| 2010 Q1 | 8412.00 CAD | 45.11% |
| 2010 Q2 | 14.2 Thousand CAD | 68.91% |
| 2010 Q3 | 41.55 Thousand CAD | 192.46% |
| 2010 Q4 | -165.66 Thousand CAD | -498.67% |
| 2010 FY | -149.67 Thousand CAD | -67.58% |
| 2009 Q2 | -4334.00 CAD | 87.08% |
| 2009 Q3 | -50.45 Thousand CAD | -1064.07% |
| 2009 Q4 | 5797.00 CAD | 111.49% |
| 2009 FY | -89.31 Thousand CAD | -97.77% |
| 2009 Q1 | -33.54 Thousand CAD | -3302.03% |
| 2008 Q1 | 2499.00 CAD | -92.2% |
| 2008 Q3 | -8883.00 CAD | -606.44% |
| 2008 Q4 | -986.00 CAD | 88.9% |
| 2008 FY | -45.16 Thousand CAD | -850.66% |
| 2008 Q2 | 1754.00 CAD | -29.81% |
| 2007 Q4 | 32.02 Thousand CAD | 0.0% |
| 2007 FY | 6016.00 CAD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Nuo Therapeutics, Inc. | -3.16 Million USD | 66.783% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -12.993% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | 59.947% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 94.103% |
| GB Sciences, Inc. | -1.42 Million USD | 25.915% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | 69.093% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -378.19% |
| Skye Bioscience, Inc. | -13.67 Million USD | 92.302% |
| Zenith Capital Corp. | -8.94 Million USD | 88.232% |
| Agentix Corp. | -1.37 Million USD | 23.281% |
| Arch Therapeutics, Inc. | -5.04 Million USD | 79.138% |
| Biomind Labs Inc. | -1 Million USD | -4.238% |
| ContraFect Corporation | -56.88 Million USD | 98.15% |
| CSL Limited | 3.7 Billion USD | 100.028% |
| CytoDyn Inc. | -18.05 Million USD | 94.172% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | 43.552% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -170.142% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 98.104% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -153.296% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 31.487% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -53.198% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 101.286% |
| SQZ Biotechnologies Company | -75.82 Million USD | 98.612% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | 47.022% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 98.534% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | 63.081% |
| Mesoblast Limited | -84.14 Million USD | 98.749% |
| Marizyme, Inc. | -34.08 Million USD | 96.913% |
| Genus plc | 6.4 Million USD | 116.444% |
| Pharming Group N.V. | -4.87 Million USD | 78.433% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 87.397% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 24.936% |
| IMV Inc. | -38.67 Million USD | 97.279% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | 61.743% |
| MultiCell Technologies, Inc. | -722.81 USD | -145497.183% |
| ONE Bio Corp. | 13.68 Million USD | 107.692% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 98.216% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 129.729% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | 63.726% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | 84.17% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -3413.592% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 93.369% |
| Alpha Cognition Inc. | -9.7 Million USD | 89.157% |
| Enzolytics Inc. | -2.14 Million USD | 51.024% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -425.04 Million USD | 99.752% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -0.804% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | 63.952% |
| Genscript Biotech Corporation | -415.79 Million USD | 99.747% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 121.413% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -302.096% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | 57.138% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -513.605% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 47.505% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 110.802% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | 76.895% |
| Adynxx, Inc. | - USD | Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| Accustem Sciences Inc. | -3.74 Million USD | 71.909% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -6.945% |
| EV Biologics, Inc. | -483.06 Thousand USD | -117.858% |
| Q BioMed Inc. | -3.44 Million USD | 69.457% |
| Capstone Therapeutics Corp. | -1.25 Million USD | 16.211% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 98.086% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| BioStem Technologies, Inc. | -7.77 Million USD | 86.471% |
| Curative Biotechnology, Inc. | -1.93 Million USD | 45.546% |
| HST Global, Inc. | -140.9 Thousand USD | -646.869% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | 21.195% |
| Wesana Health Holdings Inc. | -1.12 Million USD | 6.446% |
| Halberd Corporation | -75.05 Thousand USD | -1302.253% |
| Resverlogix Corp. | -12.74 Million USD | 91.745% |
| Cell Source, Inc. | -4.32 Million USD | 75.669% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | 33.366% |
| GeneThera, Inc. | - USD | Infinity% |
| AVAX Technologies, Inc. | 6.69 Million USD | 115.724% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -5940.933% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| NovAccess Global Inc. | -2.46 Million USD | 57.337% |
| Kadimastem Ltd | -3.04 Million USD | 65.385% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | 75.17% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -479.878% |
| LadRx Corporation | -3.82 Million USD | 72.477% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -53.198% |
| Affymax, Inc. | -15.04 Million USD | 93.006% |
| Itoco Inc. | -919.14 Thousand USD | -14.497% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | 5.953% |
| Mobile Lads Corp. | -554.55 Thousand USD | -89.774% |
| International Stem Cell Corporation | -663 Thousand USD | -58.732% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| Bioxytran, Inc. | -3.82 Million USD | 72.452% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -4081.132% |
| Qrons Inc. | -643.67 Thousand USD | -63.497% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -86.355% |
| SYBLEU INC | -149.18 Thousand USD | -605.45% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -2.22 Million USD | 52.805% |
| Rebus Holdings, Inc. | -664 Thousand USD | -58.493% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | 42.059% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -1899.223% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -5073.997% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 97.098% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | 34.957% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -43.02% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | 66.172% |
| Neutra Corp. | -229.48 Thousand USD | -358.586% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 94.0% |
| PureTech Health plc | -146.19 Million USD | 99.28% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 95.103% |
| IXICO plc | -1.43 Million USD | 26.765% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 88.912% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 99.136% |
| CSL Limited | 3.81 Billion USD | 100.028% |
| Cellectis S.A. | -108.85 Million USD | 99.033% |